✦ LIBER ✦

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

✍ Scribed by Herold, K. C.; Gitelman, S. E.; Willi, S. M.; Gottlieb, P. A.; Waldron-Lynch, F.; Devine, L.; Sherr, J.; Rosenthal, S. M.; Adi, S.; Jalaludin, M. Y.; Michels, A. W.; Dziura, J.; Bluestone, J. A.

Book ID: 120569390
Publisher: Springer
Year: 2012
Tongue: English
Weight: 386 KB
Volume: 56
Category: Article
ISSN: 0012-186X
DOI: 10.1007/s00125-012-2753-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Teplizumab (Anti-CD3 mAb) Treatment Pres

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

✍ Herold, K. C.; Gitelman, S. E.; Ehlers, M. R.; Gottlieb, P. A.; Greenbaum, C. J. 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 932 KB